2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2025)

Insulin glargine plus lixisenatide improves outcomes in Chinese adults with T2D

Treatment with iGlarLixi* resulted in better clinical outcomes than IDegAsp** in Chinese adults with type 2 diabetes (T2D), regardless of age or disease duration at baseline, according to a post hoc analysis of the phase III Soli-D study presented at ATTD-ASIA 2025.